ArticleAntimicrobial agents and chemotherapy2007
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 85 citations in OpenAlex.
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Structural comparison of substrate-binding pockets of serine β-lactamases in classes A, C, and D.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2024Review
- In Vitro Antibacterial Activity of Ceftobiprole and Comparator Compounds against Nation-Wide Bloodstream Isolates and Different Sequence Types of MRSA.Antibiotics (Basel, Switzerland) · 2024Article
- New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains.Nature microbiology · 2023Article
- Bibliometric insights into the most influential papers on antibiotic adjuvants: a comprehensive analysis.Frontiers in pharmacology · 2023Article
- Identification and metabolomic characterization of potent anti-MRSA phloroglucinol derivatives fromFrontiers in pharmacology · 2022Article
- Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.Paediatric drugs · 2021Review
- Assessment of Phenotype Relevant Amino Acid Residues in TEM-β-Lactamases by Mathematical Modelling and Experimental Approval.Microorganisms · 2021Article
- Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.International journal of molecular sciences · 2020Review
- New cephalosporins for the treatment of pneumonia in internal medicine wards.Journal of thoracic disease · 2020Review
- Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance inThe Journal of biological chemistry · 2018Article
- One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams.Protein science : a publication of the Protein Society · 2016Review
- Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).World journal of emergency surgery : WJES · 2016Review
- In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.Antimicrobial agents and chemotherapy · 2015Article
- Development of novel antibacterial drugs to combat multiple resistant organisms.Langenbeck's archives of surgery · 2015Review
- Ceftobiprole for the treatment of pneumonia: a European perspective.Drug design, development and therapy · 2015Review
- Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Drugs · 2014Review
- New antibiotics for bad bugs: where are we?Annals of clinical microbiology and antimicrobials · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interactions of ceftobiprole with purified beta-lactamases from molecular classes A, B, C, and D were determined and compared with those of benzylpenicillin, cephaloridine, cefepime, and ceftazidime. Enzymes were selected from functional groups 1, 2a, 2b, 2be, 2d, 2e, and 3 to represent beta-lactamases from organisms within the antibacterial spectrum of ceftobiprole. Ceftobiprole was refractory to hydrolysis by the common staphylococcal PC1 beta-lactamase, the class A TEM-1 beta-lactamase, and the class C AmpC beta-lactamase but was labile to hydrolysis by class B, class D, and class A extended-spectrum beta-lactamases. Cefepime and ceftazidime followed similar patterns. In most cases, the hydrolytic stability of a substrate correlated with the MIC for the producing organism. Ceftobiprole and cefepime generally had lower MICs than ceftazidime for AmpC-producing organisms, particularly AmpC-overexpressing Enterobacter cloacae organisms. However, all three cephalosporins were hydrolyzed very slowly by AmpC cephalosporinases, suggesting that factors other than beta-lactamase stability contribute to lower ceftobiprole and cefepime MICs against many members of the family Enterobacteriaceae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.